360 related articles for article (PubMed ID: 30975353)
1. Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre.
Isaza G; Donaldson L; Chaudhary V
Can J Ophthalmol; 2019 Apr; 54(2):269-274. PubMed ID: 30975353
[TBL] [Abstract][Full Text] [Related]
2. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
4. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.
Trzcionkowska K; Vehmeijer WBHJ; Kerkhoff FT; Bauer NJC; Bennebroek CAM; Dijk PH; Dijkman KP; van den Dungen FAM; Eggink CA; Feenstra RPG; Groenendaal F; van Heijst AF; van der Hoeven MAHBM; Kornelisse RF; Kraal-Biezen E; Lopriore E; Onland W; Renardel de Lavalette VW; van Rijn LJ; Schuerman FABA; Simonsz HJ; Voskuil-Kerkhof ESM; Witlox RSGM; Termote JUM; Schalij-Delfos NE
Acta Ophthalmol; 2021 Feb; 99(1):97-103. PubMed ID: 32701185
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity.
Minturn R; Hartigan K; Vegunta S; Boente C; Golzarri-Arroyo L; Hynes E; Laughlin E; Haider K; Kua KL
BMC Ophthalmol; 2024 May; 24(1):220. PubMed ID: 38790043
[TBL] [Abstract][Full Text] [Related]
6. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
7. Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity.
Vogel RN; Strampe M; Fagbemi OE; Visotcky A; Tarima S; Carroll J; Costakos DM
Ophthalmology; 2018 Mar; 125(3):444-452. PubMed ID: 29103792
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Respiratory Outcomes after Treating Retinopathy of Prematurity with Laser Photocoagulation or Intravitreal Bevacizumab.
Barry GP; Tauber KA; Greenberg S; Lajoie J; Afroze F; Oechsner H; Finucane E; Binenbaum G
Ophthalmol Retina; 2020 Dec; 4(12):1202-1208. PubMed ID: 32512055
[TBL] [Abstract][Full Text] [Related]
9. The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units.
Leng Y; Huang W; Ren G; Cai C; Tan Q; Liang Y; Yang W; Gao Z
BMC Ophthalmol; 2018 Nov; 18(1):301. PubMed ID: 30458733
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
[TBL] [Abstract][Full Text] [Related]
11. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Intensive Care Unit-based screening program for retinopathy of prematurity and its treatment in an Indian population.
Goyal A; Giridhar A; Gopalakrishnan M; Thachil T
Indian J Ophthalmol; 2019 Jun; 67(6):828-833. PubMed ID: 31124496
[TBL] [Abstract][Full Text] [Related]
14. Characteristic clinical features associated with aggressive posterior retinopathy of prematurity.
Ahn YJ; Hong KE; Yum HR; Lee JH; Kim KS; Youn YA; Park SH
Eye (Lond); 2017 Jun; 31(6):924-930. PubMed ID: 28234354
[TBL] [Abstract][Full Text] [Related]
15. Retinopathy of prematurity.
Jordan CO
Pediatr Clin North Am; 2014 Jun; 61(3):567-77. PubMed ID: 24852153
[TBL] [Abstract][Full Text] [Related]
16. Retinopathy of Prematurity Incidence and Risk Factors in a Tertiary Hospital in Riyadh, Saudi Arabia.
Al-Qahtani B; Al-Otaibi M; Alabdulajabbar K; Selayem NB; Alshehri W; Omair A; Alsaif S
Middle East Afr J Ophthalmol; 2019; 26(4):235-239. PubMed ID: 32153336
[TBL] [Abstract][Full Text] [Related]
17. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
18. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
19. Screening for retinopathy of prematurity by telemedicine in a tertiary level neonatal intensive care unit in France: Review of a six-year period.
Chan H; Cougnard-Grégoire A; Korobelnik JF; Delyfer MN; Touboul D; Coste V; Sarlangue J; Dutheil C; Paya C
J Fr Ophtalmol; 2018 Dec; 41(10):926-932. PubMed ID: 30442486
[TBL] [Abstract][Full Text] [Related]
20. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register.
Holmström G; Hellström A; Jakobsson P; Lundgren P; Tornqvist K; Wallin A
Br J Ophthalmol; 2016 Dec; 100(12):1656-1661. PubMed ID: 26969711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
